ASC Daily Briefing — July 14, 2026
No new items today. See the Standing Compliance Reference for items currently in effect.
Today’s searches surfaced only items already captured on the standing Page or in recent briefings: the CY 2027 OPPS/ASC Proposed Rule (CMS-1850-P, comment deadline August 31, 2026 — proposed 2.4% ASC payment update, IPO-list Year 2 removals, ASCQR measure changes, botulinum-toxin prior-authorization expansion, and the AO/EMTALA deeming proposal), the CY 2026 OPPS/ASC Final Rule (CMS-1834-FC) in effect (2.6% update, 560 procedures added to the ASC covered procedures list, IPO-list phase-out), the HHS Section 504 accessible medical diagnostic equipment (MDE) baseline (effective July 8, 2026) and extended Section 504 digital-accessibility deadlines (May 11, 2027 / May 10, 2028), price-transparency enforcement, the 10-state ASC prior-authorization demonstration, AAAHC v44/v45, TJC 2026 standards, the five CMS-approved ASC accreditors (AAAHC, ACHC, DNV, TJC, QUAD A), and the CMS AO-oversight final rule (Strengthening Oversight of Accrediting Organizations, published 91 FR 36467, June 16, 2026 — already tracked). No new enforcement actions, accreditation announcements, or additional Federal Register ASC notices appeared today.
Reminder: the CY 2027 Proposed Rule comment deadline (August 31, 2026) remains the next actionable date — 48 days out.